➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
AstraZeneca
Medtronic
Dow

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,119,554

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,119,554
Title:Pharma-informatics system
Abstract: Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.
Inventor(s): Zdeblick; Mark (Portola Valley, CA), Pikelny; Aleksandr (Los Angeles, CA), Robertson; Timothy (Belmont, CA), Hafezi; Hooman (Redwood City, CA)
Assignee: Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:12/949,720
Patent Claims: 1. An ingestible device comprising: a support; circuitry associated with the support; a first material electrically coupled to the circuitry and associated with the support; and a second material electrically coupled to the circuitry and associated with the support, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded monophasic signal which is conductively transmitted to a remote receiver; and wherein the circuitry comprises a switch; and wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material.

2. The device according to claim 1, wherein the support comprises a semiconductor.

3. The device according to claim 1, wherein at least one of the first material and the second material are configured to be consumed and dissolved by the electrically conductive fluid.

4. The device according to claim 3, wherein the first material comprises a metal is selected from the group consisting of magnesium, zinc, sodium, lithium and iron.

5. The device according to claim 4, wherein the first material is doped with a non-metal.

6. The device according to claim 1, wherein the second material is a salt.

7. The device according to claim 6, wherein the salt is selected from the group consisting of copper salts and iron salts.

8. The device according to claim 1, wherein the first material is a metal and the second material is a salt.

9. The device according to claim 1, wherein the device is smaller than 10 mm.sup.3.

10. The device according to claim 9, wherein the device is smaller than 1 mm.sup.3.

11. The device according to claim 1, wherein the first and second materials are electrode layers positioned on opposing sides of the support.

12. An ingestible composition comprising: (a) a device comprising: (i) a support; (ii) circuitry associated with the support; (iii) a first material electrically coupled to the circuitry; and (iv) a second material electrically coupled to the circuitry, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded monophasic signal which is conductively transmitted to a remote receiver; and wherein the circuitry comprises a switch; and wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material; and (b) a pharmaceutically acceptable carrier.

13. The composition according to claim 12, wherein at least one of the first material and the second material are configured to be consumed and dissolved by the electrically conductive fluid.

14. The composition according to claim 12, wherein the first material comprises a metal is selected from the group consisting of magnesium, zinc, sodium, lithium and iron.

15. The composition according to claim 14, wherein the first material is doped with a non-metal.

16. The composition according to claim 12, wherein the second material is a salt.

17. The composition according to claim 16, wherein the salt is selected from the group consisting of copper salts and iron salts.

18. The composition according to claim 13, wherein the first material is a metal and the second material is a salt.

19. The composition according to claim 13, wherein the composition further comprises an active agent.

20. A method of producing and ingestible device comprising: associating circuitry with a support; associating a first material with the support, wherein the first material is electrically coupled to the circuitry; and associating a second material with the support, wherein the second material is electrically coupled to the circuitry, wherein the first material is electrically isolated from the second material, wherein the first and second materials are selected to provide a voltage potential difference when in contact with an electrically conductive fluid, and wherein the circuitry is configured to modulate current flow through the electrically conductive fluid to generate an encoded signal which is conductively transmitted to a remote receiver; and wherein the circuitry comprises a switch; and wherein the circuitry is configured such that when the switch is closed, a current is produced between the first material and the second material.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Dow
McKesson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.